AI Article Synopsis
- Nanomedicines have been in development for over 40 years to improve drug absorption, distribution, and stability, but few have successfully made it to market.
- One major issue contributing to this failure is the inadequate pharmacokinetics (PK) modeling and evaluation, which hinders the optimization of these delivery systems.
- The review suggests key parameters for precise PK assessment of nanomedicines, aiming to enhance their chances of market approval and ultimately benefit patients with various diseases.
Article Abstract
Nanomedicines have been developed for more than four decades to optimize the pharmacokinetics (PK) of drugs, especially absorption, distribution, and stability in vivo. Unfortunately, only a few drug products have reached the market. One reason among others is the lack of proper PK modeling and evaluation, which impedes the optimization of these promising drug delivery systems. In this review, we discuss the specificity of nanomedicines and propose key parameters to take into account for future accurate PK evaluation of nanomedicine. We believe that this could help these innovative drug products to reach to market and change the fate of many diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.drudis.2021.04.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!